In a nutshell This study aimed to investigate using rituximab (Rituxan) and high-dose methylprednisolone (HDMP; Medrol) as a treatment for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). This study concluded that this treatment is a good option for elderly and frail patients and can work as a bridge to...
Read More
In a nutshell This study is searching for participants with advanced solid tumors including breast cancer to examine the safety and effectiveness of experimental drug avapritinib (AYVAKIT). The main outcomes to be measured are the response to treatment and side effects. This trial is being conducted in Texas, US. The details Some cancers grow as a...
Read More
In a nutshell This trial is aiming to examine the effectiveness of combination therapy with venetoclax (Venclexta), daratumumab (Darzalex), and dexamethasone (Ozurdex) with or without bortezomib (Velcade) for unresponsive or relapsed multiple myeloma (MM). The main outcome that is to be measured is the response rate, time to response,...
Read More
In a nutshell This trial is looking at the effectiveness of Quad Shot (QS) radiation therapy (RT) to relieve symptoms in patients with advanced non-small-cell lung cancer (NSCLC). The main outcome that is to be measured is the occurrence of side effects over the course of 3-months. This trial is being carried out in New Jersey and New York,...
Read More
In a nutshell This trial is examining the effectiveness and safety of short-course radiation therapy and TAS-102 (Lonsurf) plus oxaliplatin (Eloxatin) chemotherapy in rectal cancer. The main outcome to be measured will be the change in treatment response. This study is being conducted in the US. The details Colorectal cancer is one of...
Read More
In a nutshell This phase 1/2 study will investigate the safety of a new drug, BMS-986156, combined with ipilimumab (Yervoy), nivolumab (Opdivo) and radiotherapy in advanced lung cancer (LC). The main outcomes will be the rate of dose-limiting side effects and response to treatment. This trial is recruiting in Texas, US. The details...
Read MoreIn a nutshell This phase 2 study will investigate the effectiveness of experimental medication tucatinib and trastuzumab (Herceptin) to treat brain metastases in HER2-positive breast cancer (BC). The main outcome will be overall survival (OS). This trial is recruiting in Alabama and Texas, the US. The details...
Read More
In a nutshell This study is investigating how well nivolumab (Opdivo) works with DA-REPOCH chemotherapy for treating aggressive B-cell non-Hodgkin's lymphoma (NHL). The primary outcome to be measured is 2-year survival without disease progression after treatment. This study is being conducted in Columbus, OH, in the United States. The...
Read More
In a nutshell This trial will compare the effectiveness of two maintenance therapies in patients with multiple myeloma (MM) after a stem cell transplant (SCT). The main outcome to be measured will be the average time from treatment until death due to any cause. The details Maintenance therapy is commonly given after SCT to help delay...
Read MoreIn a nutshell This phase 2 trial will investigate the effect of gemcitabine (Gemzar) and nivolumab (Opdivo) in patients with metastatic small-cell lung cancer (SCLC). The main outcome will be the radiographic response rate (RRR). This trial is recruiting in North Carolina, US. The details Small cell lung cancer...
Read More
In a nutshell This phase 1b trial is examining the effectiveness and safety of a vaccine treatment, ATP128, in the treatment of advanced colorectal cancer. The main outcome to be measured is the tumor response to the treatment and treatment toxicity. This trial is being conducted in Arizona and California, US. The details Colorectal cancer is the...
Read More
In a nutshell This study examined if GVDex is as effective and safe as GVDoxil for treating Hodgkin's lymphoma (HL) that has come back or stopped responding to treatment. The authors found that GVDex was as effective as GVDoxil, with fewer side effects. Some background For most patients with HL, primary therapy is highly effective....
Read More
